Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Sci Rep. 2021 Apr 26;11(1):8919. doi: 10.1038/s41598-021-88352-y.
H-ficolin recognizes patterns on microorganisms and stressed cells and can activate the lectin pathway of the complement system. We aimed to assess H-ficolin in relation to the progression of diabetic kidney disease (DKD), all-cause mortality, diabetes-related mortality, and cardiovascular events. Event rates per 10-unit H-ficolin-increase were compared in an observational follow-up of 2,410 individuals with type 1 diabetes from the FinnDiane Study. DKD progression occurred in 400 individuals. The unadjusted hazard ratio (HR) for progression was 1.29 (1.18-1.40) and 1.16 (1.05-1.29) after adjustment for diabetes duration, sex, HbA, systolic blood pressure, and smoking status. After adding triglycerides to the model, the HR decreased to 1.07 (0.97-1.18). In all, 486 individuals died, including 268 deaths of cardiovascular causes and 192 deaths of complications to diabetes. HRs for all-cause mortality and cardiovascular mortality were 1.13 (1.04-1.22) and 1.05 (0.93-1.17), respectively, in unadjusted analyses. These estimates lost statistical significance in adjusted models. However, the unadjusted HR for diabetes-related mortality was 1.19 (1.05-1.35) and 1.18 (1.02-1.37) with the most stringent adjustment level. Our results, therefore, indicate that H-ficolin predicts diabetes-related mortality, but neither all-cause mortality nor fatal/non-fatal cardiovascular events. Furthermore, H-ficolin is associated with DKD progression, however, not independently of the fully adjusted model.
H 型ficolin 可识别微生物和应激细胞上的模式,并能激活补体系统的凝集素途径。我们旨在评估 H 型ficolin 与糖尿病肾病(DKD)进展、全因死亡率、糖尿病相关死亡率和心血管事件的关系。在 FinnDiane 研究中,对 2410 名 1 型糖尿病患者进行了观察性随访,比较了每增加 10 单位 H 型 ficolin 时的事件发生率。400 名患者发生 DKD 进展。未调整的进展风险比(HR)为 1.29(1.18-1.40),调整糖尿病病程、性别、HbA、收缩压和吸烟状况后为 1.16(1.05-1.29)。将甘油三酯加入模型后,HR 降至 1.07(0.97-1.18)。共有 486 人死亡,包括 268 例心血管原因死亡和 192 例糖尿病并发症死亡。全因死亡率和心血管死亡率的 HR 分别为 1.13(1.04-1.22)和 1.05(0.93-1.17),在未调整分析中。这些估计在调整后的模型中失去了统计学意义。然而,未调整的糖尿病相关死亡率 HR 为 1.19(1.05-1.35)和 1.18(1.02-1.37),调整水平最严格。因此,我们的结果表明 H 型 ficolin 可预测糖尿病相关死亡率,但不能预测全因死亡率或致死性/非致死性心血管事件。此外,H 型 ficolin 与 DKD 进展相关,但与完全调整后的模型无关。